Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace. More On These Topics From The Pink Sheet Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind: https://pink.citeline.com/PS149452/Project-Orbis-2023-FDA-Approves-Six-New-Cancer-Drugs-But-Partner-Nations-Lag-Behind Project Orbis: More Cancer Drugs Available In Scotland Than England: https://pink.citeline.com/PS149063/Project-Orbis-More-Cancer-Drugs-Available-In-Scotland-Than-England EMA Will Observe Project Orbis In Effort To Increase Collaboration: https://pink.citeline.com/PS148458/EMA-Will-Observe-Project-Orbis-In-Effort-To-Increase-Collaboration US FDA Eyes Project Orbis-Type Approach For Cell And Gene Therapies: https://pink.citeline.com/PS147730/US-FDA-Eyes-Project-Orbis-Type-Approach-For-Cell-And-Gene-Therapies

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related